This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Invasive fungal infections in solid organ transplant recipients
Invasive fungal infections and chronic obstructive pulmonary disease
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
Approximately 5–10% of patients who are hospitalised with influenza have been shown to end up in ICU.2–4 Once in critical care, approximately 1 in 5 patients have been shown to develop invasive aspergillosis.1,5 Influenza associated pulmonary aspergillosis (IAPA) is a severe complication and may occur in any patient, including those considered to be at low risk of developing IPA.2
Influenza-associated pulmonary aspergillosis has a high mortality rate of 47–57%1,3,6
Interval between ICU admission for influenza and IAPA diagnosis is short (<7 days, median 3 days after ICU admission)1,3,6
Up to 32% of severe influenza patients have immunosuppressive factors predisposing them to invasive pulmonary aspergillosis1,3,7
Use of corticosteroids and prolonged use of neuraminidase inhibitors, such as oseltamivir, are implicated in increased risk of IAPA (in vitro studies)5,8
Positive serum galactomannan is detected in ~50–70% of cases in the ICU
(optical density ≥1)1,3,6
Cases of influenza-associated mucormycosis (IAM) are also emerging. A review found that the majority of these patients had underlying conditions, diabetes mellitus being the most common. Risk factors overlap with IAPA, which may contribute to cases of IAM being under-diagnosed or under-reported.9
Despite advances in diagnosis and treatment, invasive fungal infection mortality remains very
high.10-14 Low clinical suspicion may cause potentially fatal delays in diagnosis and treatment2,9 and early administration of antifungal therapy is of critical importance to improve clinical outcomes.15
While there are several approved treatments for invasive aspergillosis and mucormycosis, an individualised assessment should be considered for every patient, taking into account differences in coverage, tolerability, drug interaction profile, and PK.16–19
CRESEMBA® (isavuconazole) is recommended by the ECMM as an option for the treatment of IAPA20
CRESEMBA® is indicated in adults for the treatment of:
Find out futher information about how invasive fungal infections can affect patients with COVID-19
Get quick access to further information on CRESEMBA®
ECMM, European Confederation of Medical Mycology; IAM, influenza-associated mucormycosis; IAPA, influenza-associated pulmonary aspergillosis; ICU, intensive care unit; IPA, invasive pulmonary aspergillosis; PK, pharmacokinetics.
Prescribing Information
Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information
References:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024